

## Wednesday 19th June

08:00 – 09:45	Registration			
9:45 – 10:45	Bayesian Borrowing	Decision Making	Non-technical TED	Adaptive Designs
	Digital Twins and Bayesian Dynamic Borrowing: two recent approaches for incorporating historical control data <b>Carl-Fredrik Burman</b>	Detriment Index based Ranking Technique for painkiller drugs in Noncommunicable Diseases (NCD's) <b>Samadhan Ghubade &amp; Pushkar Madhav Joshi (ICON)</b>	The Ukrainian experience: working under stressful conditions and uncertainty. <b>Angelina Rozmarytsia</b>	Defining good guidelines for futility stopping based on conditional power or predictive power <b>Christopher Jennison</b>
	Navigating Challenges in RCT Conduct: A Bayesian Adaptive Semiparametric Approach Handling Primary and Secondary Endpoints in Paediatric Trial Design <b>Danila Azzolina</b>	Assurance (probability of success) methods for designing a survival trial with a delayed treatment effect <b>James Salisbury (University of Sheffield)</b>	Emotional Intelligence for the Statistically Brilliant <b>Emma May</b>	Confidence intervals for adaptive designs <b>David Robertson</b>
			Unveiling the Power of Public Speaking to Statistician: A Path to Leadership <b>Guillaume Desachy</b>	
Bayesian Dynamic Borrowing and Prognostic Covariates: An Empirical Comparison <b>Erik Hermansson</b>	Application of Quantitative Decision Making in Early Clinical Development: A Case-Study <b>Nicola Scott (GSK)</b>	Empowering Newcomers: Fostering Connections and Knowledge <b>Kristina Weber</b>	Advanced Trial Simulation in the Design of a Pivotal Cardiovascular Study: A Case Study <b>James Matcham</b>	

			Learning Lessons: How to Run a Useful Lessons Learned Meeting and Track Actions <b>Sam Ruddell</b>	
10:45 – 11:00	<b>Changeover</b>			
11:00 – 12:30	<b>Updates on the Difficulties in Estimating Treatment Effect Heterogeneity in Clinical Trials and Observational data; Practical Examples and Benchmarking</b>	<b>Estimands in Non-inferiority Trials: Challenges in Implementation</b>	<b>Use of External Data for Safety Review</b>	<b>Career Young Session</b>
	Considerations on when and how to perform subgroup selection in Phase 2/3 programs <b>Tobias Mielke (Janssen)</b>	Non-inferiority and the estimands framework <b>Helle Lynggaard</b>	Using longitudinal Bayesian Dynamic Borrowing methodology applied to external control arms within an open label extension study. <b>Adrian Mander, Ben Hartley</b>	REMoDLing Phase II trial to incorporate historical information on a time-to-event endpoint <b>Alessandra Serra</b>
			Blinded safety signal detection integrating internal and external evidence – A Bayesian meta-analytic approach using time-to-event modelling <b>Arnab Sarkar</b>	RWD and its Practical Challenges <b>Andisheh Bakhshi</b>
			Controlled Multiple imputation in Time-To-Event data using tipping point analysis <b>Clement Daniel</b>	

	<p>Comparison of modern approaches for subgroup identification from clinical and observational data <b>David Svensson (AstraZeneca)</b></p>	<p>How the estimands framework affects choice of noninferiority margin <b>David Wright</b></p>	<p>Statistical Technology to Facilitate Safety Signal Assessment in Data Monitoring Committee (DMC) Data Review Meetings <b>Dwaine Banton</b></p>	<p>Investigating the impact of Data Monitoring Committee's recommendations on the probability of trial success (PoS) <b>Luca Rondano</b></p>
	<p>Structured approach for assessing treatment effect heterogeneity <b>Kostas Sechidis (Novartis)</b></p>		<p>Monitoring safety signals in ongoing blinded trials with Julia <b>Kristian Brock, Daniel Sabanés Bové</b></p>	<p>Seeking early conditional approval in Randomised Clinical Trials with time-to-event endpoints via historical information borrowing <b>Marco Ratta</b></p>
12:30 – 13:30	<b>Lunch</b>			
13:30 – 14:30	<b>Innovative Approaches</b>	<b>Master Protocols</b>	<b>R Sessions</b>	<b>Technical TED</b>
	<p>Implementing Innovative Statistical Methods in Pharmaceutical Drug Development <b>Margaret Jones (Weatherden consultants)</b> <b>Andy Grieve (UCB)</b></p>	<p>Practical guidance for conducting late-phase platform clinical trials: Insights from experienced UK academic clinical trials units <b>Sharon Love</b></p>	<p>Development of an AI-Enhanced Profiling Tool for R Code Optimization Using Shiny <b>Camilo Rojas, Mark Bynens</b></p>	<b>Aryelly Rodriguez</b>

	<p>Implementation of statistical innovation in a pharmaceutical company <b>Kaspar Rufibach (Roche)</b></p>	<p>Visualising master protocols <b>Deepak Parashar</b></p>	<p>Sailing, not Sinking – Journey of the First Roche Phase III Study to Use R for Primary Analysis and Potential Filing <b>Guiyuan Lei</b></p>	<p>A Bayesian approach to decision making in early development clinical trials: An R solution. <b>Audrey Yeo</b></p>
				<p>Expert Judgement to support a clinical hybrid Bayesian network approach on pancreatic cancer <b>Erica Secchettin</b></p>
				<p>A conservative approach to leveraging prior evidence about treatment effects for effective group sequential clinical trial design <b>Fabio Rigat</b></p>
	<p>Implementing Bayesian Augmented Control Designs into Business Practice: Insights and Reflections on a Journey from a Tool to a Mindset <b>Monika Jelizarow (UCB)</b></p>	<p>Designing an exploratory phase 2b platform trial in NASH with correlated co-primary binary endpoints <b>Elias Laurin Meyer</b></p>	<p>Generating reproducible company documents from R <b>Janina Linnik</b></p>	<p>CPIM: Conditional-Power-Induced Migraine: How Logical Inconsistencies lead to illogical decisions and consistent misinterpretations <b>Simon Cleall</b></p>
				<p>To Master Protocol or Not To Master Protocol? <b>Elizabeth Pilling</b></p>

14:30 – 15:00	<b>Break</b>
15:00 – 16:15	<p data-bbox="824 304 1630 339" style="text-align: center;"><b>EU HTA: readying ourselves for the road to 2025 and beyond</b></p> <p data-bbox="952 384 1503 443" style="text-align: center;">Thomas Ecker [Founder and co-CEO Ecker &amp; Ecker] Roche TBC</p> <p data-bbox="981 451 1473 510" style="text-align: center;">Manoj Chevli (Director Global HEOR Markets, BMS)</p>
16:15 – 16:30	<p data-bbox="943 555 1516 624" style="text-align: center;"><b>Closing Remarks:</b> <b>David Wright (Chair PSI Board of Directors)</b></p>